VIDEO: High dose aspacytarabine safe for acute myeloid leukemia patients over 75 years old
Click Here to Manage Email Alerts
In this video, Richard M. Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana Farber Institute, spoke with Healio about a study presented at ASCO 2021 that showed high doses of aspacytarabine are safe to use in older patients with acute myeloid leukemia.
In the study of 46 patients with AML, 15 patients reached complete remission following one or two treatment courses. The researchers concluded that the treatment should be considered a safe and efficacious alternative for patients who are unfit for chemotherapy, a population that often includes older adults.
"There was a 30% to 35% complete response rate, which is pretty good for largely relapsed/refractory patients," Stone said.
Collapse
Altman J, et al. Abstract 7007. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts